In this issue:
First-line rabbit ATG dose for acquired aplastic anaemia
Sirolimus successful in refractory/relapsed acquired pure red-cell aplasia
eGVHD app for assessing GVHD
Antibiotics for febrile neutropenia in adolescents/young adults vs. younger patients
Ruxolitinib + azacitidine in myelofibrosis
Ruxolitinib in elderly patients with myelofibrosis
Rivaroxaban not for high-risk antiphospholipid syndrome
Second malignancies following myeloproliferative neoplasms
Thalidomide before and after SCT in MM
Please login below to download this issue (PDF)